ABOS Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -- compared to Acumen Pharmaceuticals's net margin of --. Acumen Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of $9.20, signalling upside risk potential of 673.11%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 437.19%. Given that Acumen Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe Acumen Pharmaceuticals is more attractive than Nanoviricides.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.225%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Acumen Pharmaceuticals's net income of -$29.8M is lower than Nanoviricides's net income of -$2M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Acumen Pharmaceuticals's net margin of --. Acumen Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of $9.20, signalling upside risk potential of 673.11%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 362.75%. Given that Acumen Pharmaceuticals has higher upside potential than Oragenics, analysts believe Acumen Pharmaceuticals is more attractive than Oragenics.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Acumen Pharmaceuticals's net income of -$29.8M is lower than Oragenics's net income of -$3.3M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus 1.35x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Acumen Pharmaceuticals's net margin of -2357.27%. Acumen Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of $9.20, signalling upside risk potential of 673.11%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 957.24%. Given that Palatin Technologies has higher upside potential than Acumen Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Acumen Pharmaceuticals.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Acumen Pharmaceuticals's net income of -$29.8M is lower than Palatin Technologies's net income of -$2.4M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Acumen Pharmaceuticals's net margin of --. Acumen Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of $9.20, signalling upside risk potential of 673.11%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 426.32%. Given that Acumen Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Acumen Pharmaceuticals is more attractive than Theriva Biologics.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Acumen Pharmaceuticals's net income of -$29.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.